

INNOVATIVE

COLLABORATIVE

SCALEABLE

ACTIONABLE

SECURE

With the rapid emergence of SARS-CoV-2 variants, there is rising concern over the detection of new viral strains using the existing diagnostic assays. Diagnostic manufacturers, governments, researchers, and large companies requiring employees to be tested have a vested interest in understanding these variants.

In collaboration with the United States National Institutes of Health's (NIH) RADx initiative, ROSALIND

launched its web-based platform for monitoring the emergence of SARS-CoV-2 variants as a solution for companies to evaluate the effects on the performance of diagnostic tests. The ROSALIND Diagnostic Monitoring System [ROSALIND DxM] provides the following:

- Secure, scalable web-based system
- Intuitive User Interface with Protection of Proprietary Test Information
- Advanced Analysis to Assess and Manage Risk
- Reagent Coverage and Mismatch Incident Dashboards
- Integrated BioInformatics pipeline (GISAID, GenBank, and FASTA import)

TO LEARN MORE, VISIT https://www.rosalind.bio/dxm


ROSALIND DxM

ROSALIND truly believes in Research Reimagined! Our goal is to provide you a secure, intuitive, web-based user interface that allows you the ability to quickly get to the relevant, actionable information you need. Here are a few highlights:

Genome Browser Summary




Incident Summary Table



Detail History Trend



Incident Coverage Map



Whether you are a diagnostic manufacturer, large enterprise, or research scientist, let ROSALIND DxM help you identify, analyze and mitigate potential impacts of SARS-CoV-2 variants.

